SI2989110T1 - Derivati tamoksifena za zdravljenje neoplastičnih bolezni, predvsem z višjo stopnjo proteina HER2 - Google Patents

Derivati tamoksifena za zdravljenje neoplastičnih bolezni, predvsem z višjo stopnjo proteina HER2

Info

Publication number
SI2989110T1
SI2989110T1 SI201430928T SI201430928T SI2989110T1 SI 2989110 T1 SI2989110 T1 SI 2989110T1 SI 201430928 T SI201430928 T SI 201430928T SI 201430928 T SI201430928 T SI 201430928T SI 2989110 T1 SI2989110 T1 SI 2989110T1
Authority
SI
Slovenia
Prior art keywords
treatment
protein level
neoplastic diseases
her2 protein
high her2
Prior art date
Application number
SI201430928T
Other languages
English (en)
Slovenian (sl)
Inventor
Jiri Neuzil
Jan Stursa
Lukas Werner
Original Assignee
Smart Brain s.r.o.
Biotechnologicky Ustav Av Cr, V.V.I.
Jiri Neuzil
Kkcg Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2989110(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ304553B6/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Smart Brain s.r.o., Biotechnologicky Ustav Av Cr, V.V.I., Jiri Neuzil, Kkcg Ag filed Critical Smart Brain s.r.o.
Publication of SI2989110T1 publication Critical patent/SI2989110T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
SI201430928T 2013-04-24 2014-04-07 Derivati tamoksifena za zdravljenje neoplastičnih bolezni, predvsem z višjo stopnjo proteina HER2 SI2989110T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ304553B6 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
EP14721738.4A EP2989110B1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (1)

Publication Number Publication Date
SI2989110T1 true SI2989110T1 (sl) 2019-01-31

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430928T SI2989110T1 (sl) 2013-04-24 2014-04-07 Derivati tamoksifena za zdravljenje neoplastičnih bolezni, predvsem z višjo stopnjo proteina HER2

Country Status (21)

Country Link
US (1) US9896466B2 (cg-RX-API-DMAC7.html)
EP (1) EP2989110B1 (cg-RX-API-DMAC7.html)
JP (1) JP6375091B2 (cg-RX-API-DMAC7.html)
KR (1) KR101764991B1 (cg-RX-API-DMAC7.html)
CN (1) CN105452265B (cg-RX-API-DMAC7.html)
AU (1) AU2014256546B2 (cg-RX-API-DMAC7.html)
CA (1) CA2909994C (cg-RX-API-DMAC7.html)
CY (1) CY1120821T1 (cg-RX-API-DMAC7.html)
DK (1) DK2989110T3 (cg-RX-API-DMAC7.html)
EA (1) EA029881B1 (cg-RX-API-DMAC7.html)
ES (1) ES2699099T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186868B (cg-RX-API-DMAC7.html)
HR (1) HRP20181872T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042239T2 (cg-RX-API-DMAC7.html)
MD (1) MD4626C1 (cg-RX-API-DMAC7.html)
NZ (1) NZ713589A (cg-RX-API-DMAC7.html)
PL (1) PL2989110T3 (cg-RX-API-DMAC7.html)
PT (1) PT2989110T (cg-RX-API-DMAC7.html)
SI (1) SI2989110T1 (cg-RX-API-DMAC7.html)
UA (1) UA116469C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014173374A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
BR112018000088B1 (pt) * 2015-07-03 2022-07-12 Bayer Cropscience Aktiengesellschaft Derivados de n-(1,3,4-oxadiazol-2-il)aril carboxamida com ação herbicida, seu uso, composição herbicida, e método para controle de plantas indesejadas
EP3368011A4 (en) * 2016-07-12 2019-07-10 Accutar Biotechnology Inc. NOVEL CONNECTIONS AND USE THEREOF
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3079952A1 (en) 2017-10-24 2019-05-02 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
SG11202004729QA (en) 2017-11-24 2020-06-29 Lunella Biotech Inc Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
CA3085375A1 (en) 2017-12-20 2019-06-27 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives
EP3955935A4 (en) * 2019-04-16 2023-01-18 Lunella Biotech, Inc. ALKYL-TPP COMPOUNDS FOR MITOCHONDRIAL TARGETING AND ANTI-CANCER TREATMENTS
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551434B1 (en) * 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
JP4648319B2 (ja) * 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
USRE47300E1 (en) * 2008-03-14 2019-03-19 Cancure Limited Mitochondrially delivered anti-cancer compounds
US20100297262A1 (en) * 2009-04-17 2010-11-25 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
JP2016522179A (ja) 2016-07-28
NZ713589A (en) 2017-12-22
CN105452265B (zh) 2017-05-10
HK1216317A1 (zh) 2016-11-04
EA201591918A1 (ru) 2016-02-29
US20160075726A1 (en) 2016-03-17
PT2989110T (pt) 2018-11-15
UA116469C2 (uk) 2018-03-26
US9896466B2 (en) 2018-02-20
PL2989110T3 (pl) 2019-03-29
MD4626C1 (ro) 2019-11-30
CN105452265A (zh) 2016-03-30
EA029881B1 (ru) 2018-05-31
CY1120821T1 (el) 2019-12-11
GEP20186868B (en) 2018-06-25
MD20150117A2 (ro) 2016-08-31
JP6375091B2 (ja) 2018-08-15
MD4626B1 (ro) 2019-04-30
WO2014173374A1 (en) 2014-10-30
KR20150144756A (ko) 2015-12-28
HUE042239T2 (hu) 2019-06-28
ES2699099T3 (es) 2019-02-07
CA2909994A1 (en) 2014-10-30
DK2989110T3 (en) 2018-12-03
EP2989110B1 (en) 2018-08-08
AU2014256546A1 (en) 2015-11-12
CA2909994C (en) 2018-06-26
KR101764991B1 (ko) 2017-08-10
EP2989110A1 (en) 2016-03-02
AU2014256546B2 (en) 2017-03-30
HRP20181872T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
SI2989110T1 (sl) Derivati tamoksifena za zdravljenje neoplastičnih bolezni, predvsem z višjo stopnjo proteina HER2
IL243976A0 (en) kdm1a inhibitors for disease treatment
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
HUE054397T2 (hu) Antitestkészítmények daganatkezelésre
HUE048541T2 (hu) Claudin 18.2 ellenes antitesteket magában foglaló terápia rák kezelésére
SG11201507496UA (en) N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
HUE046702T2 (hu) Eljárások üvegcsontbetegség kezelésére
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
EP3007756A4 (en) Catheter-assisted tumor treatment
PL2959903T3 (pl) Lek do leczenia chorób oczu
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
GB201314386D0 (en) Treatment system for aquaculture
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
IL244755B (en) process to create xanthohumol
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
EP2991650A4 (en) Methods for the treatment of cancer
SG11201508061UA (en) Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency
HUE040536T2 (hu) Eljárás halogén-N,N-dimetilbenzilaminok elõállítására
EP3047857A4 (en) Treatment for hemorrhagic diseases by anti-protein-c antibody
HK40097140A (zh) 治疗线粒体疾病的方法
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
HK40032828A (en) Methods for the treatment of mitochondrial disease